Clinical Study of Approved Contact Lenses
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 271
- Registration Number
- NCT03351101
- Locations
- 🇺🇸
Valeant Site 04, Denver, Colorado, United States
🇺🇸valeant Site 02, San Diego, California, United States
🇺🇸Valeant Site 03, San Francisco, California, United States
Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 43
- Registration Number
- NCT03282929
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Wegenerstrasse 13, Germany
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Completed
- Conditions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 3
- Registration Number
- NCT03145025
- Locations
- 🇺🇸
Valeant Site 001, Boston, Massachusetts, United States
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 15
- Registration Number
- NCT03098953
- Locations
- 🇺🇸
Valeant Site 01, Inglewood, California, United States
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 600
- Registration Number
- NCT02786901
- Locations
- 🇺🇸
Valeant Site 01, Phoenix, Arizona, United States
🇺🇸Valeant Site 02, Saint Louis, Missouri, United States
🇺🇸Valeant Site 05, Miami, Florida, United States
A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 396
- Registration Number
- NCT02701556
- Locations
- 🇺🇸
Kannarr EyeCare, Pittsburg, Kansas, United States
Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 600
- Registration Number
- NCT02394379
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 20
- Registration Number
- NCT02394340
- Locations
- 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 38
- Registration Number
- NCT02258139
- Locations
- 🇺🇸
Indiana University, Bloomington, Indiana, United States
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 326
- Registration Number
- NCT02208297
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath